Takeda (TAK) affiliate plans Rule 144 sale of 27,197 ADSs

Rhea-AI Filing Summary

An affiliate of Takeda Pharmaceutical Company Limited plans to sell up to 27,197 American Depositary Shares (ADSs) of Takeda through Interactive Brokers LLC on or after July 13, 2026 under Rule 144. These ADSs come from 61,830 ADSs acquired on July 1, 2026 via vested Restricted Stock Unit Awards granted as compensation. The ADSs are listed on the NYSE, with 143,310,556 ADSs outstanding.

Key Figures

Planned ADSs to be sold: 27,197 ADSs Aggregate market value of ADSs: $455,544.81 ADSs outstanding: 143,310,556 ADSs +2 more

5 metrics

Planned ADSs to be sold 27,197 ADSs Maximum number of Takeda ADSs planned for sale under Rule 144

Aggregate market value of ADSs $455,544.81 Estimated market value of the 27,197 ADSs to be sold

ADSs outstanding 143,310,556 ADSs Total Takeda ADSs reported outstanding in connection with the notice

ADSs acquired from RSU vesting 61,830 ADSs Takeda ADSs acquired on July 1, 2026 via vested Restricted Stock Unit Awards

Planned sale date 07/13/2026 Date the Takeda ADSs are expected to be sold on the NYSE

Key Terms

American Depositary Shares (ADSs), Restricted Stock Unit Awards, compensation, Rule 144

4 terms

American Depositary Shares (ADSs) financial

"American Depositary Shares (ADSs) | Interactive Brokers LLC"

A U.S.-listed certificate that stands for a specific number of shares in a non‑U.S. company held by a U.S. bank, making the foreign stock tradable on American exchanges in dollars. Think of it like a local voucher that represents ownership of an overseas product — it lets U.S. investors buy and sell foreign companies without handling foreign currency or foreign brokerage accounts, but it can affect dividends, voting rights, fees, liquidity and exposure to currency and regulatory differences.

Restricted Stock Unit Awards financial

"ADSs | 07/01/2026 | Restricted Stock Unit Awards - Vested."

Restricted stock unit awards are company promises to deliver a specific number of shares to employees or service providers in the future once conditions—such as staying with the company for a set time or meeting performance targets—are met. They matter to investors because when the promises convert into actual shares they increase the total share count and can reduce earnings per share, while also aligning recipients’ interests with stock performance much like deferred pay that turns into ownership if goals are met.

compensation financial

"61830 | 07/01/2026 | Compensation"

Rule 144 regulatory

"144: Securities Information American Depositary Shares (ADSs)"

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/13/2026 - 06:32 AM Accepted by SEC EDGAR 07/13/2026 - 06:24 AM Learn about SEC filing dates

FAQ

What volume of Takeda (TAK) ADSs is planned for sale under this Rule 144 notice?

The notice covers a planned sale of up to 27,197 American Depositary Shares (ADSs) of Takeda Pharmaceutical Company Limited. This planned disposition is to be executed through Interactive Brokers LLC on or after July 13, 2026 on the NYSE.

What is the approximate market value of the Takeda (TAK) ADSs covered by this planned sale?

The planned sale involves ADSs with an aggregate market value of about $455,544.81. This value reflects the estimated market price for the 27,197 ADSs that may be sold under the Rule 144 notice on the NYSE.

How were the Takeda (TAK) ADSs to be sold under Rule 144 originally acquired?

The ADSs were acquired through Restricted Stock Unit Awards that vested on July 1, 2026. In total, 61,830 ADSs were obtained as compensation, forming the pool from which the Rule 144 sale of 27,197 ADSs is planned.

When is the planned sale date for the Takeda (TAK) ADSs listed in this Rule 144 notice?

The planned sale date for the Takeda ADSs is July 13, 2026. The ADSs are expected to be sold on the NYSE through Interactive Brokers LLC, subject to market conditions and applicable Rule 144 requirements.

How many Takeda (TAK) ADSs are reported as outstanding in connection with this Rule 144 sale?

The notice references 143,310,556 ADSs of Takeda Pharmaceutical Company Limited as outstanding. This figure provides context for the market float and scale relative to the planned 27,197 ADS sale under Rule 144.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
American Depositary Shares (ADSs)	Interactive Brokers LLC One Pickwick Plaza Greenwich CT 06830	27197	455544.81	143310556	07/13/2026	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
ADSs	07/01/2026	Restricted Stock Unit Awards - Vested.	Takeda Pharmaceutical Company Limited			61830	07/01/2026	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)